Bibliography
- McElroy WD, Glass B (Eds.), Johns Hopkins University Press, Baltimore, MD (1957):609–614.
- Cancer: Principles and Practice of Oncology (Fourth Edition). DeVita V. Hellman S, Rosenberg S (Eds.), JB Lippincott Company, Philadelphia (1993).
- HEIDELBERGER C, et al.: Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature (1957) 179:663–666.
- JOHNSON et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. (1995) 55:1407–1412.
- American Cancer Society Textbook of Clinical Oncology. Holleb A, Fink D, Murphy G (Eds.), (1991).
- JACKMAN AL, TAYLOR GA, GIBSON W, et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579–5586.
- JACKMAN AL, KIMBELL R, AHERNE GW, et al.: The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, non-polyglutamable quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res. In Press.
- JACKMAN AL, KELLAND LR, KIMBELL R, et al.: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer (1995) 71:914–924.
- JACKMAN AL, et al.: ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer (1995) 31A(7/8):1277–1282.
- JACKMAN AL, et al. Unpublished data.
- SHIH C, et al.: LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase and thymidylate synthase: multiple folate enzymes inhibition. Ann. OncoL (1996) 7\(Suppl. 1):85.
- Sahota A, Taylor MW (Eds.), Adv. Exp. Med. Biol. (1995) 370:801–804.
- Sahota A, Taylor M (Eds.), Adv. Exp. Med. (1995) 370:185–188.
- SHIH C, et al.: LY231514, a pyrrolo 12,3-dlpyrimidine based antifolate that inhibits multiple folate requiring enzymes. Cancer Res. (1997) 57. In press.
- WEBBER S, et al.: AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. PharmacoL (1996) 37:509–517.
- BLACKSTOCK AW, COX Al, TEPPER JE: Treatment of pancreatic cancer: current limitations, future possibilities. Oncology (1996) 10(3):301–318.
- FARMER DG, ROSOVE MH, SHAKED A, BUSUTTIL RW: Current treatment modalities for hepatocellular carcinoma. Ann. Surg. (1994) 219(3):236–247.